Verrica Pharmaceuticals financials
$4.46−3.04%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $35.6M | $7.6M | $5.1M | $9.0M | $12.0M | $0.00 | — | — |
| Gross profit | $32.1M | $4.8M | $4.4M | $9.0M | $12.0M | $0.00 | — | — |
| Gross margin | 90.3% | 63.8% | 85.4% | 100.0% | 100.0% | — | — | — |
| Operating income | -$11.9M | -$65.8M | -$63.2M | -$21.3M | -$30.9M | -$40.2M | -$30.1M | -$21.9M |
| Net income | -$17.9M | -$76.6M | -$67.0M | -$24.5M | -$35.1M | -$42.7M | -$28.2M | -$20.6M |
| Net margin | −50.3% | −1012.1% | −1307.5% | −271.1% | −292.3% | — | — | — |
| Diluted EPS | $-1.68 | $-14.78 | $-14.80 | $-7.20 | $-13.00 | $-17.10 | $-11.30 | $-14.10 |
| EBITDA | -$11.8M | -$65.5M | -$62.7M | -$20.6M | -$30.4M | -$40.0M | -$29.8M | -$21.9M |
| Operating cash flow | -$17.6M | -$60.9M | -$38.6M | -$18.6M | -$27.6M | -$30.2M | -$27.4M | -$17.9M |
| Free cash flow | -$17.6M | -$61.0M | -$38.9M | -$19.0M | -$28.5M | -$31.7M | -$28.1M | -$18.6M |
| Diluted shares | 10.7M | 5.2M | 4.5M | 3.4M | 2.7M | 2.5M | 2.5M | 1.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $30.1M | $46.3M | $69.5M | $34.3M | $15.8M | $10.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $54.6M | $54.8M |
| Total debt | $1.0M | $45.0M | $44.3M | $0.00 | $41.7M | $35.3M |
| Total assets | $47.1M | $54.1M | $81.6M | $44.7M | $80.1M | $74.2M |
| Total liabilities | $22.4M | $64.0M | $61.8M | $4.7M | $47.5M | $41.2M |
| Shareholders' equity | $24.7M | -$9.9M | $19.8M | $40.0M | $32.6M | $33.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology